We’ve written extensively about various cellular therapy approaches in hematologic malignancies involving T cells and natural killer (NK) cells over the last few years, but if we are to see significant lasting success in solid tumours then we may need to consider the involvement of other immune cells.
Indeed, if they can be engineered in some way to enhance the anti-tumour response then they might turn out to rather useful in combination with existing established approaches such as checkpoint blockade as a way to generate more responses.
How do we go about achieving this state?
There are some very intriguing and different approaches in early development that we plan to follow over time. Here, we explore this potential and the possibilities through our latest in-depth expert interview…